Advertisement

New Oral Immunotherapy for Grass Allergies Approved — Physician’s First Watch

Medical News |
April 16, 2014

New Oral Immunotherapy for Grass Allergies Approved

By Kristin J. Kelley

The FDA has approved Grastek, a second sublingual immunotherapy to treat grass pollen allergies. (The first sublingual immunotherapy for grass allergies, Oralair, was approved earlier this month.) The new tablet contains Timothy grass extracts and is indicated for patients aged 5 to 65 years.

In December 2013, FDA advisers called for postapproval studies to test Grastek's safety in children aged 5 to 11 years, citing side effects such as lip swelling and oral blistering.

Reader Comments (1)

Jesse McRae, M.D. Physician, Allergy/Immunology, Florida

This seems to be welcome news to patients with grass-induced allergic rhinitis. However, the tablets do not contain Bahia or Bermuda grass extracts, both of which are major grass allergens in the southeast. Additionally, neither Bahia nor Bermuda cross-reacts with Timothy vastly limiting the usefulness of this therapy in the south.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement